Ronald Richard - 05 Dec 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role: Director
Signature: /s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol: EBS
Transactions as of: 05 Dec 2025
Net transactions value: -$263,080
Form type: 4
Filing time: 09 Dec 2025, 18:01:01 UTC
Previous filing: 02 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Richard Ronald	Director	300 PROFESSIONAL DR, GAITHERSBURG	/s/ Richard S. Lindahl, Attorney-in-fact	09 Dec 2025	0001380177

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EBS	Common Stock	Sale	$85,990	-7,100	-6.7%	$12.11	98,417	05 Dec 2025	Direct	F1, F2
transaction	EBS	Common Stock	Options Exercise	$129,255	+25,748	+26%	$5.02	124,165	05 Dec 2025	Direct
transaction	EBS	Common Stock	Tax liability	$129,258	-10,864	-8.7%	$11.90	113,301	05 Dec 2025	Direct	F3, F4
transaction	EBS	Common Stock	Sale	$177,087	-14,884	-13%	$11.90	98,417	05 Dec 2025	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EBS	Stock Option (Right to Buy)	Options Exercise	$0	-25,748	-100%	$0.000000	0	05 Dec 2025	Common Stock	25,748	$5.02	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
F2	The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12.
F3	Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise.
F4	The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.
F5	Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025.